retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 Retatrutide, a (GLP1, GIP, glucagon), just released trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished π§π΅π² ππ³π³π²π°π πΌπ³ πππ£-π π₯π²π°π²π½ππΌπΏ
Pay in 4 interest-free payments of $7.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 6 - Aug 11




























